🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. Pegylated Interferon Alfa-2a

    Hoffmann-La Roche

    Chronic Myelogenous Leukemia

    phase 3 small molecule completed

    1 trial

  2. Pembrolizumab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 3 mab active

    1 trial

  3. Pembrolizumab

    Merck KGaA, Darmstadt, Germany

    Metastatic Esophageal Squamous Cell Carcinoma

    phase 3 mab active

    1 trial

  4. Peramivir+SOC

    Biocryst

    Cough

    phase 3 small molecule terminated

    1 trial

  5. Placebo

    Regeneron UK Limited

    Heterozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  6. Placebo

    Menarini Group

    Acute Pain

    phase 3 small molecule completed

    1 trial

  7. Placebo

    Regeneron UK Limited

    Gout

    phase 3 small molecule completed

    1 trial

  8. Placebo

    Sumitomo Pharma (Suzhou) Co.,

    Bipolar Depression

    phase 3 small molecule completed

    1 trial

  9. Placebo

    Vertex Pharmaceuticals (Australia) Pty.

    Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

    phase 3 small molecule completed

    1 trial

  10. Placebo

    Hoffmann-La Roche

    Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  11. Placebo Rosuvastatin Calcium 20 mg tablets, ROSUVASTATIN CALCIUM

    The George Institute

    Venous thromboembolism, Pulmonary Embolism, Deep Vein Thrombosis

    phase 3 small molecule active

    1 trial

  12. Placebo de fasturtec, Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion.

    Pari Pharma GmbH

    Patients hospitalised in intensive care, diagnosed with sepsis less than 48 hours ago, uric acid level ≥200µmol/L, adults, negative G6PD deficiency

    phase 3 small molecule active

    1 trial

  13. Placebo de formule développée spécifiquement pour la recherche par la PUI (cf IMPD-Q), CLOBETASOL PROPIONATE

    Pari Pharma GmbH

    Adult patients with symptomatic and inflammatory Hand osteoarthritis HOA.

    phase 3 small molecule active

    1 trial

  14. Placebo double encapsulated oral transplant of fecal microbiota, Double encapsulated oral transplant of fecal microbiota

    Pari Pharma GmbH

    Adults Non Diabete Remission (NDR) Type 2 Diabete (T2D) patients 1 to 5 years after bariatric surgery

    phase 3 small molecule active

    1 trial

  15. Placebo double encapsulated oral transplant of fecal microbiota, Double encapsulated oral transplant of fecal microbiota

    Pari Pharma GmbH

    Patients colonized with MDR-GNB

    phase 3 small molecule active

    1 trial

  16. Placebo for AMG 145, EVOLOCUMAB

    Amgen

    Adults at high risk of cardiovascular events without prior MI or stroke.

    phase 3 small molecule active

    1 trial

  17. Placebo for Acetylsalicylic Acid, ACETYLSALICYLIC ACID, REGN7508, Placebo for REGN7508

    Lacuna Pharma Pty Ltd

    Symptomatic Venous Thromboembolism (VTE)

    phase 3 small molecule active

    1 trial

  18. Placebo for BMS-936558, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb Australia Pty Ltd

    Subjects with resected adenocarcinoma or squamous cell carcinoma esophageal or gastroesophageal junction cancer

    phase 3 small molecule active

    1 trial

  19. Placebo for cemdisiran is 0.9% saline and will be supplied by the sponsor., Pozelimab, Placebo for pozelimab will be provided in an aqueous buffered solution and supplied by the sponsor., Cemdisiran

    Lacuna Pharma Pty Ltd

    Geographic Atrophy Secondary to Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  20. Placebo for mepolizumab is a 0.9% sodium chloride solution in a syringe for subcutaneous injection., PREDNISOLONE, MEPOLIZUMAB, METHYLPREDNISOLONE, PREDNISONE, Placebo for benralizumab for clinical trials is a sterile liquid solution presented in an accessorized prefilled syringe (apfs) for subcutaneous injection., Fasenra 30 mg solution for injection in pre-filled syringe

    AstraZeneca AB

    Eosinophilic Granulomatosis with Polyangiitis (EGPA)

    phase 3 small molecule active

    1 trial

  21. Placebo for pembrolizumab, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE , FLUOROURACIL , OXALIPLATIN , CISPLATIN

    Merck Sharp and Dohme

    Gastric and gastric esophageal junction (GEJ) adenocarcinoma

    phase 3 small molecule active

    1 trial

  22. Placebo injection, 0.8 ml is a sterile, preservative-free, parenteral solution of sodium chloride and riboflavin in water for injection (wfi) intended for subcutaneous injection, ISIS 678354

    IONIS PHARMACEUTICALS INC

    Severe Hypertriglyceridemia.

    phase 3 small molecule active

    1 trial

  23. Placebo intramuscular injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Spontaneous Uriticaria

    phase 3 small molecule active

    1 trial

  24. Placebo is a solution for infusion of human albumin 1%, is an albumin preparation manufactured by dilution from the drug product of Albiomin 20%, it will be administrated via intravenous infusion., Trimodulin (human IgM, IgA, IgG solution)

    Biotest Pharma GmbH

    Non-severe community-acquired pneumonia (CAP) or moderate or severe Coronavirus Disease 2019 (COVID-19)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources